Atrial fibrillation patients with CHA2DS2-VASc >1 benefit from oral anticoagulation prior to cardioversion

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Electrical cardioversion for atrial fibrillation carries an embolic stroke risk, typically managed within 48 hours.
• The study investigates thromboembolism and bleeding risks associated with cardioversion in patients with and without oral anticoagulation.

Purpose of the Study:

• To compare thromboembolic and bleeding complications after electrical cardioversion in atrial fibrillation patients.
• To determine the safety of cardioversion in patients with and without pre-treatment with oral anticoagulation.

Main Methods:

• Retrospective analysis of 22,874 patients undergoing electrical cardioversion for atrial fibrillation from Swedish national health registries (2006-2010).
• Outcomes measured included thromboembolism and bleeding events within 30 days post-cardioversion.
• Statistical adjustments were made using CHA2DS2-VASc for stroke risk and HAS-BLED for bleeding risk, alongside propensity score matching.

Main Results:

• Patients with low stroke risk (CHA2DS2-VASc 0-1) experienced no thromboembolic events within 30 days.
• Patients without oral anticoagulation showed a significantly higher risk of thromboembolic complications (OR 2.54; 95% CI 1.70-3.79) after adjustment and matching.
• No significant differences in bleeding complications were found between patients with or without oral anticoagulation.

Conclusions:

• Electrical cardioversion without prior oral anticoagulation is potentially unsafe for atrial fibrillation patients with risk factors for thromboembolism (CHA2DS2-VASc score >1).
• The findings highlight the importance of assessing stroke risk and considering anticoagulation before cardioversion.